Last reviewed · How we verify
pramipexole or ropinirole
Pramipexole and ropinirole are dopamine agonists that activate dopamine receptors in the brain, mimicking the action of dopamine.
Pramipexole and ropinirole are dopamine agonists that activate dopamine receptors in the brain, mimicking the action of dopamine. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | pramipexole or ropinirole |
|---|---|
| Sponsor | Desitin Arzneimittel GmbH |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
This leads to increased dopamine activity in the brain, which can help alleviate symptoms of Parkinson's disease and restless legs syndrome. By activating dopamine receptors, these drugs can also help regulate movement and reduce symptoms of these conditions.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyskinesia
Key clinical trials
- Butrans for Treatment of Restless Legs Syndrome (PHASE4)
- Switching From Oral Dopamine Agonists to Rotigotine (PHASE4)
- Naltrexone for Impulse Control Disorders in Parkinson's Disease (PHASE4)
- A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease (PHASE3)
- A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease (PHASE3)
- A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease (PHASE4)
- MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (PHASE3)
- Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pramipexole or ropinirole CI brief — competitive landscape report
- pramipexole or ropinirole updates RSS · CI watch RSS
- Desitin Arzneimittel GmbH portfolio CI